New tlr-4 antagonist aptamers
HK40137518APending Publication Date: 2026-09-11MERCK PATENT GMBH
0 Cites 0 Cited by
Patent Information
- Application Number
- HK62026127031
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2026-08-04
- Publication Date
- 2026-09-11
Abstract
It is provided an aptamer comprising the polynucleotide sequence consisting of SEQ ID NO: 7, a fragment thereof or a functionally equivalent variant thereof, comprising at least chemically modified nucleotides, with a length between 40 and 100 nucleotides and having the capability of specifically binding to TLR-4 and inhibiting TLR-4 activation. The chemically modified aptamers which derive from SEQ ID NO: 7 or its variants, have increased stability and a positive effect in breast cancer and inflammatory autoimmune neuropathy disorder such as Guillain-Barré syndrome.
Need to check novelty before this filing date? Find Prior Art
